Dosing strategies for gene therapies
In this article, our gene therapy experts at Health Advances, Parexel’s commercial strategy group, outline considerations for competitively positioning your gene therapy.
The original goal of gene therapy was to deliver a single administration that would maintain therapeutic effectiveness over a patient’s lifetime. This ‘one and done’ model appears to have worked for some gene therapies, with promising follow-up data evidenced. However, in some instances, including gene therapies for hemophilia, a single dose may not be enough, and redosing may be required.
In this article, our gene therapy experts at Health Advances, Parexel’s commercial strategy group, outline considerations for ’one-and-done’ versus redosing therapies.